Alexander W Wyatt

List of Publications by Year
in descending order

73 papers	5,784 citations	126858 33 h-index	85498 71 g-index
75 all docs	75 docs citations	75 times ranked	7294 citing authors

#	Article	IF	Citations
1	Molecular tumor heterogeneity in muscle invasive bladder cancer: Biomarkers, subtypes, and implications for therapy. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 287-294.	0.8	28
2	Quality and Quantity: Evaluating Tumor Biology Alongside Novel Imaging on Diagnosis of Metastatic Hormone-sensitive Prostate Cancer. European Urology, 2022, 81, 437-439.	0.9	0
3	Somatic Features of Response and Relapse in Nonâ€“muscle-invasive Bladder Cancer Treated with Bacillus Calmette-GuÃ©rin Immunotherapy. European Urology Oncology, 2022, 5, 677-686.	2.6	6
4	Genomic Features of Lung-Recurrent Hormone-Sensitive Prostate Cancer. JCO Precision Oncology, 2022, 6, e2100543.	1.5	7
5	Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assay. NAR Cancer, 2022, 4, .	1.6	4
6	Androgen receptor genomic alterations and treatment resistance in metastatic prostate cancer. Prostate, 2022, 82, .	1.2	6
7	Genomic biomarkers to guide precision radiotherapy in prostate cancer. Prostate, 2022, 82, .	1.2	3
8	BRCA2, ATM, and CDK12 Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression. Clinical Cancer Research, 2021, 27, 1650-1662.	3.2	52
9	Clinical implications of genomic alterations in metastatic prostate cancer. Prostate Cancer and Prostatic Diseases, 2021, 24, 310-322.	2.0	12
10	Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer. Journal of Pathology: Clinical Research, 2021, 7, 311-325.	1.3	19
11	Differential treatment outcomes in BRCA1/2â€, CDK12â€, and ATMâ€mutated metastatic castrationâ€resistant prostate cancer. Cancer, 2021, 127, 1965-1973.	2.0	15
12	Building confidence in circulating tumour DNA assays for metastatic castration-resistant prostate cancer. Nature Reviews Urology, 2021, 18, 255-256.	1.9	4
13	Increased Pathway Complexity Is a Prognostic Biomarker in Metastatic Castration-Resistant Prostate Cancer. Cancers, 2021, 13, 1588.	1.7	1
14	Blood Biomarker Landscape in Patients with High-risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as They Progress to Metastatic Disease. Clinical Cancer Research, 2021, 27, 4539-4548.	3.2	6
15	Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition. Clinical Cancer Research, 2021, 27, 4610-4623.	3.2	41
16	Quantitative and Qualitative Analysis of Blood-based Liquid Biopsies to Inform Clinical Decision-making in Prostate Cancer. European Urology, 2021, 79, 762-771.	0.9	47
17	Olaparib for the treatment of metastatic prostate cancer. Future Oncology, 2021, 17, 2413-2429.	1.1	2
18	Technical and biological constraints on ctDNA-based genotyping. Trends in Cancer, 2021, 7, 995-1009.	3.8	33

#	Article	IF	Citations
19	B2B: Prostate Cancer. SociÃ©tÃ© Internationale D'urologie Journal, 2021, 2, S30-S50.	0.2	0
20	Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer. Journal of Clinical Oncology, 2021, 39, 2926-2937.	0.8	36
21	Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group Meeting Summary. Urology, 2021, 155, 165-171.	0.5	11
22	Development of secondary urothelial carcinoma following complete response to immune checkpoint inhibitors. Urology Case Reports, 2021, 39, 101762.	0.1	0
23	Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer. Nature Communications, 2021, 12, 184.	5.8	85
24	Considerations on the identification and management of metastatic prostate cancer patients with DNA repair gene alterations in the Canadian context. Canadian Urological Association Journal, 2021, 16, .	0.3	2
25	Tissue- and Blood-derived Genomic Biomarkers for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review. European Urology Oncology, 2021, 4, 914-923.	2.6	23
26	Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer. European Urology, 2020, 77, 333-341.	0.9	65
27	Plasma Circulating Tumor DNA and Clonal Hematopoiesis in Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2020, 18, 322-331.e2.	0.9	30
28	Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate Cancer. Clinical Cancer Research, 2020, 26, 1114-1125.	3.2	57
29	The DNA methylation landscape of advanced prostate cancer. Nature Genetics, 2020, 52, 778-789.	9.4	198
30	Concurrent germline and somatic pathogenic BAP1 variants in a patient with metastatic bladder cancer. Npj Genomic Medicine, 2020, 5, 12.	1.7	9
31	Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer. European Urology, 2020, 78, 834-844.	0.9	47
32	Circulating Tumour DNA as a Biomarker Source in Metastatic Prostate Cancer. SociÃ©tÃ© Internationale D'urologie Journal, 2020, 1, 39-48.	0.2	3
33	Immunocytochemistry for ARID1A as a potential biomarker in urine cytology of bladder cancer. Cancer Cytopathology, 2019, 127, 578-585.	1.4	16
34	Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 573.e19-573.e29.	0.8	13
35	Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial. Lancet Oncology, The, 2019, 20, 1730-1739.	5.1	227
36	Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 826-836.	0.8	33

#	Article	IF	Citations
37	Randomized Phase 1 Trial of Pembrolizumab with Sequential Versus Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial Carcinoma. European Urology, 2019, 75, 707-711.	0.9	89
38	Evaluation of Commercial Circulating Tumor DNA Test in Metastatic Prostate Cancer. JCO Precision Oncology, 2019, 3, 1-9.	1.5	26
39	Reply to Rodolfo Montironi, Liang Cheng, Marina Scarpelli, Alessia Cimadamore, Francesco Montorsi, and Antonio Lopez-Beltran's Letter to the Editor re: Gillian Vandekerkhove, Werner J. Struss, Matti Annala, et al. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. Eur Urol 2019;75:667â€“75: How Does Circulating DNA Reach the Blood Stream?. European Urology, 2019, 76, e73-e74.	0.9	0
40	Plasma Androgen Receptor Copy Number Status at Emergence of Metastatic Castration-Resistant Prostate Cancer: A Pooled Multicohort Analysis. JCO Precision Oncology, 2019, 3, 1-13.	1.5	15
41	Biomarkers for Programmed Deathâ€1 Inhibition in Prostate Cancer. Oncologist, 2019, 24, 444-448.	1.9	18
42	Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. European Urology, 2019, 75, 667-675.	0.9	131
43	DNA repair defects in prostate cancer: impact for screening, prognostication and treatment. BJU International, 2019, 123, 769-776.	1.3	35
44	Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer. Cancer Discovery, 2018, 8, 444-457.	7.7	376
45	Predicting therapy response and resistance in metastatic prostate cancer with circulating tumor DNA. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 380-384.	0.8	13
46	Clinical utility of emerging liquid biomarkers in advanced prostate cancer. Cancer Genetics, 2018, 228-229, 151-158.	0.2	11
47	Frequent mutation of the FOXA1 untranslated region in prostate cancer. Communications Biology, 2018, 1, 122.	2.0	21
48	Isolation and genome sequencing of individual circulating tumor cells using hydrogel encapsulation and laser capture microdissection. Lab on A Chip, 2018, 18, 1736-1749.	3.1	21
49	Biallelic tumour suppressor loss and DNA repair defects in de novo smallâ€cell prostate carcinoma. Journal of Pathology, 2018, 246, 244-253.	2.1	32
50	Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell, 2018, 174, 758-769.e9.	13.5	459
51	Molecular Dissection of Complete Response to Receptor Tyrosine Kinase Inhibition in Type II Papillary Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2017, 15, e145-e150.	0.9	1
52	Her2 alterations in muscle-invasive bladder cancer: Patient selection beyond protein expression for targeted therapy. Scientific Reports, 2017, 7, 42713.	1.6	85
53	Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repairâ€“deficient Prostate Cancer. European Urology, 2017, 72, 34-42.	0.9	179
54	Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors. Cancer Discovery, 2017, 7, 999-1005.	7.7	223

#	Article	IF	Citations
55	Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy. Clinical Cancer Research, 2017, 23, 6802-6811.	3.2	69
56	Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer. Clinical Cancer Research, 2017, 23, 6487-6497.	3.2	121
57	Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer. Journal of the National Cancer Institute, 2017, 109, .	3.0	288
58	The Master Neural Transcription Factor BRN2 Is an Androgen Receptorâ€“Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer. Cancer Discovery, 2017, 7, 54-71.	7.7	285
59	Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients. Genome Biology, 2016, 17, 10.	3.8	165
60	Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer. JAMA Oncology, 2016, 2, 1598.	3.4	290
61	Moving Toward Personalized Care: Liquid Biopsy Predicts Response to Cisplatin in an Unusual Case of BRCA2-Null Neuroendocrine Prostate Cancer. Clinical Genitourinary Cancer, 2016, 14, e233-e236.	0.9	15
62	Targeting the adaptive molecular landscape of castrationâ€resistant prostate cancer. EMBO Molecular Medicine, 2015, 7, 878-894.	3.3	110
63	Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2015, 21, 2315-2324.	3.2	407
64	The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer. Cell Reports, 2015, 12, 922-936.	2.9	216
65	High Fidelity Patient-Derived Xenografts for Accelerating Prostate Cancer Discovery and Drug Development. Cancer Research, 2014, 74, 1272-1283.	0.4	304
66	Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer. Genome Biology, 2014, 15, 426.	3.8	71
67	A Meta-Analysis Approach for Characterizing Pan-Cancer Mechanisms of Drug Sensitivity in Cell Lines. PLoS ONE, 2014, 9, e103050.	1.1	7
68	In Brief: Chromothripsis and cancer. Journal of Pathology, 2013, 231, 1-3.	2.1	15
69	The diverse heterogeneity of molecular alterations in prostate cancer identified through next-generation sequencing. Asian Journal of Andrology, 2013, 15, 301-308.	0.8	39
70	nFuse: Discovery of complex genomic rearrangements in cancer using high-throughput sequencing. Genome Research, 2012, 22, 2250-2261.	2.4	67
71	Polyâ€gene fusion transcripts and chromothripsis in prostate cancer. Genes Chromosomes and Cancer, 2012, 51, 1144-1153.	1.5	46
72	Integrated genome and transcriptome sequencing identifies a novel form of hybrid and aggressive prostate cancer. Journal of Pathology, 2012, 227, 53-61.	2.1	63

#	Article	IF	Citations
73	From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. Journal of Pathology, 2012, 227, 286-297.	2.1	161